David A. Fellows Sells 9,305 Shares of Nightstar Therapeutics PLC (NASDAQ:NITE) Stock

Nightstar Therapeutics PLC (NASDAQ:NITE) CEO David A. Fellows sold 9,305 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $25.31, for a total value of $235,509.55. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

NASDAQ NITE traded up $0.01 on Friday, hitting $25.60. 2,000 shares of the company traded hands, compared to its average volume of 361,712. The company has a market capitalization of $719.36 million, a PE ratio of -15.71 and a beta of 3.38. Nightstar Therapeutics PLC has a 52-week low of $9.59 and a 52-week high of $29.55.

Several institutional investors have recently made changes to their positions in NITE. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. purchased a new position in shares of Nightstar Therapeutics in the fourth quarter valued at about $127,000. Janney Montgomery Scott LLC purchased a new position in shares of Nightstar Therapeutics in the third quarter valued at about $204,000. JPMorgan Chase & Co. purchased a new position in shares of Nightstar Therapeutics in the third quarter valued at about $214,000. Virtus ETF Advisers LLC purchased a new position in shares of Nightstar Therapeutics in the fourth quarter valued at about $314,000. Finally, Squarepoint Ops LLC increased its holdings in shares of Nightstar Therapeutics by 106.7% in the fourth quarter. Squarepoint Ops LLC now owns 43,886 shares of the company’s stock worth $506,000 after purchasing an additional 22,651 shares during the last quarter. Institutional investors and hedge funds own 39.35% of the company’s stock.

A number of research firms have commented on NITE. Barclays lowered Nightstar Therapeutics from an “overweight” rating to an “equal weight” rating and reduced their target price for the stock from $28.00 to $26.00 in a report on Monday, March 25th. Chardan Capital reissued a “buy” rating on shares of Nightstar Therapeutics in a report on Monday, March 4th. Leerink Swann lowered Nightstar Therapeutics from an “outperform” rating to a “market perform” rating and set a $25.18 target price for the company. in a report on Tuesday, March 5th. Svb Leerink lowered Nightstar Therapeutics from an “outperform” rating to a “market perform” rating and cut their price objective for the stock from $35.00 to $25.50 in a report on Tuesday, March 5th. Finally, Mizuho lowered Nightstar Therapeutics from a “buy” rating to a “neutral” rating and lifted their price objective for the stock from $22.00 to $25.50 in a report on Tuesday, March 5th. Eight analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $27.06.

ILLEGAL ACTIVITY WARNING: “David A. Fellows Sells 9,305 Shares of Nightstar Therapeutics PLC (NASDAQ:NITE) Stock” was originally posted by Baseball Daily News and is the property of of Baseball Daily News. If you are reading this report on another site, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this report can be viewed at https://www.baseballdailydigest.com/news/2019/04/26/nightstar-therapeutics-plc-nite-ceo-sells-235509-55-in-stock.html.

About Nightstar Therapeutics

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia.

Further Reading: What are retained earnings?

Receive News & Ratings for Nightstar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nightstar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.